One of the first ALK TKIs that emerged for advanced ALK+ NSCLC treatment was crizotinib, approved by the Food and Drug Administration (FDA) in 2011, which demonstrated significant results, but eventually developed resistance mechanisms [101]. This evidence concerns the gene ALK and non-small cell lung carcinoma.